inriver Showcases Innovations and Customer Success at PIMpoint Europe 2023
9.5.2023 09:00:00 EEST | Business Wire | Press release
inriver, the leading software company powering the entire product journey with revenue-driving product information management (PIM) across every customer touchpoint, today unveiled a significant new product innovation and showcased leading brand partners at PIMpoint Europe 2023, its annual conference and the world’s largest product information management event.
This year’s event is highlighted by inriver’s new breed of PIM, an evolution of traditional product information management solutions. As a result of this new breed of PIM, inriver announced continued product innovation to the inriver PIM platform, including ChatGPT functionality to create efficiencies for augmenting product data, and further showcased the power of its now-available syndication capabilities. These innovations have allowed inriver to deliver even more operational efficiency, built-in digital shelf analytics, expanded sales opportunities, and greater sustainability benefits.
“We face unprecedented demand for more sustainability from brands, retailers, and manufacturers as a result of our increasingly circular economy. PIMpoint Europe 2023 comes at such a pivotal moment for our community,” said Niels Stenfeldt, inriver CEO. “As the world prepares for the European Union’s new Digital Product Passport initiative, the new breed of PIM turns global demands for supply chain transparency into new growth drivers for manufacturing companies. There is no better time to welcome our peers across so many industries for meaningful conversations for the future.”
Joining inriver are customer and partner showcases led by leading brands such as Michelin, Victorinox, Öob, Fluidra and more. These brands represent world-class PIM users that inriver helps create, enrich, and syndicate product information across a variety of channels and marketplaces.
Another brand, and inriver customer appearing at PIMpoint is Lantmännen, Northern Europe’s leader in agriculture, machinery, bioenergy and food products. Owned by 18,000 Swedish farmers and with 10,000 employees, Lantmännen has operations in over 20 countries and an annual revenue of approximately SEK 60 billion.
“Lantmännen has a long-term approach to farming, taking an active role in creating more sustainable energy and food supply. We take responsibility from field to fork and focus on issues that are of importance for sustainable, profitable, and thriving farming,” said Håkan Jägbrink, Platform Manager for the IT Commercial Backbone at Lantmännen. “As we are building a sustainable value chain across multiple companies and industries, Lantmännen requires our product data to be complete and accurate. The inriver PIM solution allows us to connect the data across people, processes, and our metadata structure for our 7 different companies. The inriver PIM’s flexible, elastic data model powers our product journey to drive efficiencies and cost reductons. Further, inriver is developing in exactly the right direction for our upcoming requirements.”
In addition to product innovations, brand, and partner showcases, inriver also announced the recipients of the 2022 inriver awards. The awards highlight organizations and individuals leading the industry and driving change in digital commerce and product information management. PIMpoint Europe Award winners:
- 2022 Alliance Ambassador of the Year, Global — Salesforce
- 2022 Alliance Partner of the Year, Global — Bynder
- 2022 Customer of the Year, EMEA — Fluidra
- 2022 Customer Ambassador of the Year, EMEA — Christopher Klumpp, Victorinox
- 2022 Partner of the Year, EMEA — Nexer
- 2022 Partner Project of the Year, EMEA — Nexer for Lantmännen
- 2022 Community Ambassador of the Year, Global — Mark Stuart-Walker, Luceco plc
“This has been a truly awe-inspiring year for the PIM community and the recipients of the 2022 inriver awards are not only being recognized for industry-leading PIM use cases, projects, and innovation but for their dedication to collaboration and business transformation,” said Brooke Cunningham, Chief Marketing Officer, inriver. “This year’s winning customers are leading from the front with their product information strategies, and these partners are committed to helping our joint customers power their entire product journeys. On behalf of the inriver leadership team, I want to thank each and every award recipient for their contribution to driving successful business outcomes.”
PIMpoint is made possible by the inriver valued partner ecosystem and the role it plays in delivering impactful customer stories, including the PIMpoint 2023 Global sponsors Optimizely and Nexer, as well as Europe sponsors Bynder, Delaware, Digizuite, Lengoo, Transperfect, Aprimo, Diamir Consulting, FotoWare, Geta, Immeo, Tietoevry, Etac, Avensia, ChannelEngine, Cypoint Inspire AB, Mad Max Consulting, Priint, and Xsarus.
In addition to customer and partner momentum in the Nordics market, inriver continues to invest in leadership and talent to support its local workforce. Ulrica Falkenberg has recently been appointed as Chief People and Culture Officer for the company based in Stockholm. An accomplished executive and Swedish national, Falkenberg most recently served as CHRO at Trustly, a digital payments company, and has served as an executive at Alumni Harvey Nash, an Executive Talent firm, as well as Max Mara Fashion Group.
About inriver
inriver powers the entire product journey at every touchpoint. The inriver configurable PIM solution, with built-in digital shelf analytics and integration capabilities, connects to your digital ecosystem with flexibility and ease, so it grows as your company grows. With more demands on product data than ever before, B2B and B2C enterprises need a PIM solution that supports the entire product cycle, from sourcing to decommissioning and every stage in between.
inriver helps brands, manufacturers, and retailers turn product information into strategic assets, maximizing profitability at every touchpoint for 1,600+ global brands. Headquartered in Malmö, Sweden, and with offices worldwide, inriver has a team of over 375 people ready to strengthen your product journey. For more information, visit inriver.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005195/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom